Qianjiang Yongan Pharmaceutical 将来の成長

Future 基準チェック /06

We currently don't have sufficient analyst coverage to forecast growth and revenue for Qianjiang Yongan Pharmaceutical.

主要情報

n/a

収益成長率

n/a

EPS成長率

Pharmaceuticals 収益成長	19.3%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	None
最終更新日	n/a

今後の成長に関する最新情報

更新なし

Recent updates

Qianjiang Yongan Pharmaceutical (SZSE:002365) Is Paying Out A Dividend Of CN¥0.10

Jul 01

Investors Aren't Buying Qianjiang Yongan Pharmaceutical Co., Ltd.'s (SZSE:002365) Revenues

Feb 27

このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Qianjiang Yongan Pharmaceutical は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。

シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。

業績と収益の成長予測

SZSE:002365 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
9/30/2024	789	3	-17	120	N/A
6/30/2024	820	-16	-35	94	N/A
3/31/2024	858	1	49	168	N/A
12/31/2023	973	-12	100	221	N/A
9/30/2023	1,142	25	171	312	N/A
6/30/2023	1,214	80	245	412	N/A
3/31/2023	1,361	105	239	410	N/A
1/1/2023	1,462	140	238	387	N/A
9/30/2022	1,563	187	252	358	N/A
6/30/2022	1,680	177	193	265	N/A
3/31/2022	1,664	151	105	167	N/A
1/1/2022	1,565	108	39	102	N/A
9/30/2021	1,407	73	36	85	N/A
6/30/2021	1,304	59	30	110	N/A
3/31/2021	1,268	108	100	190	N/A
12/31/2020	1,173	106	102	207	N/A
9/30/2020	1,252	134	110	239	N/A
6/30/2020	1,307	150	156	264	N/A
3/31/2020	1,310	88	138	250	N/A
12/31/2019	1,370	90	105	240	N/A
9/30/2019	1,287	96	51	208	N/A
6/30/2019	1,143	105	22	199	N/A
3/31/2019	1,057	139	23	228	N/A
12/31/2018	1,005	178	45	314	N/A
9/30/2018	1,016	164	-20	354	N/A
6/30/2018	1,011	168	N/A	277	N/A
3/31/2018	982	152	N/A	278	N/A
12/31/2017	933	133	N/A	197	N/A
9/30/2017	766	132	N/A	95	N/A
6/30/2017	688	100	N/A	102	N/A
3/31/2017	606	79	N/A	58	N/A
12/31/2016	549	62	N/A	85	N/A
9/30/2016	567	50	N/A	116	N/A
6/30/2016	544	39	N/A	108	N/A
3/31/2016	541	21	N/A	60	N/A
12/31/2015	556	18	N/A	71	N/A
9/30/2015	598	19	N/A	48	N/A
6/30/2015	681	25	N/A	43	N/A
3/31/2015	661	36	N/A	48	N/A
12/31/2014	658	32	N/A	19	N/A
9/30/2014	594	29	N/A	27	N/A
6/30/2014	562	23	N/A	53	N/A
3/31/2014	535	14	N/A	36	N/A
12/31/2013	523	23	N/A	64	N/A

アナリストによる今後の成長予測

収入対貯蓄率: Insufficient data to determine if 002365's forecast earnings growth is above the savings rate (2.9%).

収益対市場: Insufficient data to determine if 002365's earnings are forecast to grow faster than the CN market

高成長収益: Insufficient data to determine if 002365's earnings are expected to grow significantly over the next 3 years.

収益対市場: Insufficient data to determine if 002365's revenue is forecast to grow faster than the CN market.

高い収益成長: Insufficient data to determine if 002365's revenue is forecast to grow faster than 20% per year.

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: Insufficient data to determine if 002365's Return on Equity is forecast to be high in 3 years time

Qianjiang Yongan Pharmaceutical 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.032 (vs CN¥0.034 loss in 3Q 2023)

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: EPS: CN¥0.081 (vs CN¥0.14 in 2Q 2023)

Qianjiang Yongan Pharmaceutical (SZSE:002365) Is Paying Out A Dividend Of CN¥0.10

Insufficient new directors

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Qianjiang Yongan Pharmaceutical Co., Ltd., Annual General Meeting, Jun 21, 2024

First quarter 2024 earnings released: EPS: CN¥0.097 (vs CN¥0.051 in 1Q 2023)

Full year 2023 earnings released: CN¥0.042 loss per share (vs CN¥0.48 profit in FY 2022)

Investor sentiment deteriorates as stock falls 16%

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Investors Aren't Buying Qianjiang Yongan Pharmaceutical Co., Ltd.'s (SZSE:002365) Revenues

Investor sentiment deteriorates as stock falls 27%

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 19, 2024

Third quarter 2023 earnings released: CN¥0.034 loss per share (vs CN¥0.15 profit in 3Q 2022)

New minor risk - Profit margin trend

Full year 2022 earnings released: EPS: CN¥0.48 (vs CN¥0.38 in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.13 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.13 in 2Q 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.07 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.32 in 2Q 2020)

Qianjiang Yongan Pharmaceutical Co., Ltd. (SZSE:002365) completed the acquisition of 35% stake in Wuhan Low-dimensional Materials Research Institute Co., Ltd. from Li Ganghui and Wuhan Xinlian Huida Technology Investment Partnership (Limited Partnership).

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.027 (vs CN¥0.017 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.37 (vs CN¥0.31 in FY 2019)

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day low: CN¥8.66

New 90-day low: CN¥9.00

New 90-day low: CN¥10.03

New 90-day low: CN¥10.32

Third quarter earnings released

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 23, 2020

New 90-day low: CN¥11.10

New 90-day low: CN¥11.63

Earnings released

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘